Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2016-03, Vol.67 (3), p.532-533
Hauptverfasser:	Habbig, Sandra, MD, Bergmann, Carsten, MD, Weber, Lutz T., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Atypical Hemolytic Uremic Syndrome - drug therapy Atypical Hemolytic Uremic Syndrome - genetics Atypical Hemolytic Uremic Syndrome - physiopathology Complement Factor H - genetics Humans Immunologic Factors - administration & dosage Mutation Nephrology Pharmacogenetics - methods Precision Medicine Secondary Prevention Withholding Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!